Claudia Tregnago

Dr. Claudia Tregnago

University of Padova - Department of Woman and Child Health
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in Cell Reports
Verified
Journal Article
Open access
LSLuca Simula
Luca Simula
IPIlenia Pacella
Ilenia Pacella
ACAlessandra Colamatteo
Alessandra Colamatteo
CPClaudio Procaccini
Claudio Procaccini
VCValeria Cancila
Valeria Cancila
SCSilvia Campello
Silvia Campello
Mitochondria are key players in the regulation of T cell biology by dynamically responding to cell needs, but how these dynamics integrate in T cells is still poorly understood. We show here that the mitochondrial pro-fission protein Drp1 fosters migration and expansion of developing thymocytes both in vitro and in vivo. In addition, we find that Drp1 sustains in vitro clonal expansion and cMyc-dependent metabolic reprogramming upon activation, also regulating effector T cell numbers in vivo. Migration and extravasation defects are also exhibited in Drp1-deficient mature T cells, unveiling its crucial role in controlling both T cell recirculation in secondary lymphoid organs and accumulation at tumor sites. Moreover, the observed Drp1-dependent imbalance toward a memory-like phenotype favors T cell exhaustion in the tumor microenvironment. All of these findings support a crucial role for Drp1 in several processes during T cell development and in anti-tumor immune-surveillance.

19 May 2021 in Blood
Verified
Journal Article
Closed access
PDF file
GBGiulia Borella
Giulia Borella
ARAmbra Da Ros
Ambra Da Ros
EPElena Porcú
Elena Porcú
CTClaudia Tregnago
Claudia Tregnago
MBMaddalena Benetton
Maddalena Benetton
MARTINA PIGAZZIMARTINA PIGAZZI
MARTINA PIGAZZI
Bone marrow (BM) microenvironment contributes to the regulation of normal hematopoiesis through a finely tuned balance of self-renewal and differentiation processes, cell-cell interaction and secretion of cytokines that during leukemogenesis are altered and favor tumor cell growth. In pediatric acute myeloid leukemia (AML), chemotherapy is the standard of care, but still >30% of patients relapse. The need to accelerate the evaluation of innovative medicines prompted us to investigate the mesenchymal stromal cells (MSCs) role in the leukemic niche to define its contribution to the mechanisms of leukemia escape. We generated humanized three-dimensional (3D) niche with AML cells and MSCs derived from either patients (AML-MSCs) or healthy donors. We observed that AML cells establish physical connections with MSCs, mediating a reprogrammed transcriptome inducing aberrant cell proliferation and differentiation, and severely compromising their immunomodulatory capability. We confirmed that AML cells modulate h-MSCs transcriptional profile promoting functions similar to the AML-MSCs when co-cultured in vitro, thus facilitating leukemia progression. Conversely, MSCs derived from BM of patients at time of disease remission showed recovered healthy features, at transcriptional and functional levels, including the secretome. We proved that AML blasts alter MSCs activities in the BM niche, favoring disease development and progression. We discovered that a novel AML-MSCs selective CaV1.2 channel blocker drug, Lercanidipine, is able to impair leukemia progression in 3D niche both in vitro and when implanted in vivo, if used in combination with chemotherapy, supporting the hypothesis that synergistic effects can be obtained by dual targeting approaches.

28 November 2016 in Leukemia
Verified
Journal Article
Closed access
PDF file
VBV Bisio
V Bisio
MZMatteo Zampini
Matteo Zampini
CTClaudia Tregnago
Claudia Tregnago
EME Manara
E Manara
Valentina SalsiValentina Salsi
Valentina Salsi
MARTINA PIGAZZIMARTINA PIGAZZI
MARTINA PIGAZZI

10 July 2014 in Blood
Verified
Journal Article
Closed access
PDF file
EMElena Manara
Elena Manara
EBEmma Baron
Emma Baron
CTClaudia Tregnago
Claudia Tregnago
SASanja Aveic
Sanja Aveic
VBValeria Bisio
Valeria Bisio
MARTINA PIGAZZIMARTINA PIGAZZI
MARTINA PIGAZZI
A rare location, t(6;11)(q27;q23) (MLL-AF6), is associated with poor outcome in childhood acute myeloid leukemia (AML). The described mechanism by which MLL-AF6, through constitutive self-association and in cooperation with DOT-1L, activates aberrant gene expression does not explain the biological differences existing between t(6;11)-rearranged and other MLL-positive patients nor their different clinical outcome. Here, we show that AF6 is expressed in the cytoplasm of healthy bone marrow cells and controls rat sarcoma viral oncogene (RAS)-guanosine triphosphate (GTP) levels. By contrast, in MLL-AF6-rearranged cells, AF6 is found localized in the nucleus, leading to aberrant activation of RAS and of its downstream targets. Silencing MLL-AF6, we restored AF6 localization in the cytoplasm, thus mediating significant reduction of RAS-GTP levels and of cell clonogenic potential. The rescue of RAS-GTP levels after MLL-AF6 and AF6 co-silencing confirmed that MLL-AF6 oncoprotein potentiates the activity of the RAS pathway through retention of AF6 within the nucleus. Exposure of MLL-AF6-rearranged AML blasts to tipifarnib, a RAS inhibitor, leads to cell autophagy and apoptosis, thus supporting RAS targeting as a novel potential therapeutic strategy in patients carrying t(6;11). Altogether, these data point to a novel role of the MLL-AF6 chimera and show that its gene partner, AF6, is crucial in AML development. Key Points MLL-AF6 leads to aberrant activation of RAS and its downstream targets. RAS targeting is a novel potential therapeutic strategy in AML patients carrying t(6;11).

25 October 2012 in Haematologica
Verified
Journal Article
Closed access
MARTINA PIGAZZIMARTINA PIGAZZI
MARTINA PIGAZZI
EME. Manara
E. Manara
SBSilvia Bresolin
Silvia Bresolin
CTClaudia Tregnago
Claudia Tregnago
ABA. Beghin
A. Beghin
GBG. Basso
G. Basso
MicroRNA-34b down-regulation in acute myeloid leukemia was previously shown to induce CREB overexpression, thereby causing leukemia proliferation in vitro and in vivo. The role of microRNA-34b and CREB in patients with myeloid malignancies has never been evaluated. We examined microRNA-34b expression and the methylation status of its promoter in cells from patients diagnosed with myeloid malignancies. We used gene expression profiling to identify signatures of myeloid transformation. We established that microRNA-34b has suppressor ability and that CREB has oncogenic potential in primary bone marrow cell cultures and in vivo. MicroRNA-34b was found to be up-regulated in pediatric patients with juvenile myelomonocytic leukemia (n=17) and myelodysplastic syndromes (n=28), but was down-regulated in acute myeloid leukemia patients at diagnosis (n=112). Our results showed that hypermethylation of the microRNA-34b promoter occurred in 66% of cases of acute myeloid leukemia explaining the low microRNA-34b levels and CREB overexpression, whereas preleukemic myelodysplastic syndromes and juvenile myelomonocytic leukemia were not associated with hypermethylation or CREB overexpression. In paired samples taken from the same patients when they had myelodysplastic syndrome and again during the subsequent acute myeloid leukemia, we confirmed microRNA-34b promoter hypermethylation at leukemia onset, with 103 CREB target genes differentially expressed between the two disease stages. This subset of CREB targets was confirmed to associate with high-risk myelodysplastic syndromes in a separate cohort of patients (n=20). Seventy-eight of these 103 CREB targets were also differentially expressed between healthy samples (n=11) and de novo acute myeloid leukemia (n=72). Further, low microRNA-34b and high CREB expression levels induced aberrant myelopoiesis through CREB-dependent pathways in vitro and in vivo. In conclusion, we suggest that microRNA-34b controls CREB expression and contributes to myeloid transformation from both healthy bone marrow and myelodysplastic syndromes. We identified a subset of CREB target genes that represents a novel transcriptional network that may control myeloid transformation.

5 December 2014 in Haematologica
Verified
Journal Article
Open access
PDF file
MARTINA PIGAZZIMARTINA PIGAZZI
MARTINA PIGAZZI
EME. Manara
E. Manara
BBBarbara Buldini
Barbara Buldini
VBV. Beqiri
V. Beqiri
VBV. Bisio
V. Bisio
GBG. Basso
G. Basso
Disease relapse still remains the most important cause of treatment failure in childhood acute myeloid leukemia (AML). Molecular monitoring of response to treatment by minimal residual disease (MRD) provides important information, widely used to tailor treatment in childhood acute lymphoblastic